Braidwell LP Increases Position in Oruka Therapeutics, Inc. $ORKA

Key Points

• Braidwell LP increased its stake in Oruka Therapeutics by 37.0%, owning 4.20% of the company valued at approximately $16.1 million after buying an additional 424,750 shares.
• Oruka Therapeutics stock is currently down 3.1% at $14.80, with a 52-week price range of $5.49 to $33.00 and a market cap of $554.26 million.
• Analysts maintain a generally positive outlook on Oruka Therapeutics, with multiple firms issuing "buy" ratings and a consensus target price of $40.38 for the stock.

Braidwell LP increased its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 37.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,572,426 shares of the company's stock after acquiring an additional 424,750 shares during the period. Braidwell LP owned approximately 4.20% of Oruka Therapeutics worth $16,133,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in shares of Oruka Therapeutics in the 4th quarter worth approximately $54,000. Squarepoint Ops LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter worth approximately $236,000. AlphaQuest LLC acquired a new stake in shares of Oruka Therapeutics in the 1st quarter worth approximately $168,000. Jane Street Group LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter worth approximately $343,000. Finally, Cannon Global Investment Management LLC acquired a new stake in shares of Oruka Therapeutics in the 1st quarter worth approximately $195,000. Institutional investors and hedge funds own 56.44% of the company's stock.

Oruka Therapeutics Stock Down 3.0%

Shares of ORKA stock traded down $0.47 during mid-day trading on Thursday, hitting $14.97. 89,619 shares of the company's stock were exchanged, compared to its average volume of 242,522. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $31.13. The stock has a 50-day simple moving average of $14.15 and a two-hundred day simple moving average of $11.79. The stock has a market cap of $560.63 million, a price-to-earnings ratio of -5.33 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.02. As a group, analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 12th. HC Wainwright reiterated a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Monday, August 18th. Wall Street Zen cut Oruka Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Finally, BTIG Research assumed coverage on Oruka Therapeutics in a report on Thursday, May 22nd. They set a "buy" rating on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $40.38.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.